Medicare Advantage and Prescription Drug Plan Monitoring Methods Recompete
Forecast Recompete Updated
- Agency
-
Centers for Medicare and Medicaid Services
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $2,000,000 to $5,000,000
- Set-aside
- No set-aside
Forecast facts
- Incumbent contract
-
- 47QRAA20D0072 Federal IDV award held by L&M Policy Research, LLC Ordering ends Jun 14, 2030 · Ceiling $2,400,000
- Anticipated award
- Through
- Acquisition strategy
- Follow-on to Existing Contract
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Forecast number
- 270257
- Points of contact
Forecast details come from CMS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Centers for Medicare and Medicaid Services is conducting a competitive recompete for Medicare Advantage and Prescription Drug Plan monitoring methods development, with solicitation release estimated for April 1, 2027, and award targeted for July 15, 2027. The contractor shall review and analyze CMS's Medicare Advantage (Part C) and Prescription Drug (Part D) programs for monitoring approaches applicable to sponsors, including Medicare-Medicaid Plans, and further develop monitoring methods for selected approaches. This is a firm fixed-price engagement with a four-year period of performance beginning September 30, 2027.
The estimated award value ranges from $2 million to $5 million. Performance occurs in Washington, DC. Points of contact are Dawn Wilkins, Contracting Officer, at dawn.wilkins@cms.hhs.gov or 410-786-8588, and David McLachlan at david.mclachlan@cms.hhs.gov or 410-786-4391, both at the Centers for Medicare and Medicaid Services.
This recompete replaces Federal Supply Schedule contract 47QRAA20D0072, awarded to L&M Policy Research, LLC, a women-owned small business, on June 15, 2020, with a $2.4 million ceiling. Under that contract, CMS issued a $3.5 million firm fixed-price delivery order in September 2023 for Medicare Advantage and Prescription Drug Plan monitoring methods, performed in Washington, DC, with completion due September 29, 2027.
Forecast text
The contractor shall: 1) review and analyze the CMS’ Medicare Advantage (Part C) and Prescription Drug (Part D) programs for approaches to monitor sponsors, incorporating the Medicare-Medicaid Plans as applicable; and, 2) further develop monitoring methods for selected approaches.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast